# OncoMyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncomyx

- Industry: Biotechnology
- Headquarters: Phoenix, US
- Website: www.oncomyx.com
- Total disclosed funding: $58M
- Latest round: Series B (Nov 19, 2021)
- Investors on record: 10

## About

OncoMyx, Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies aimed at delivering targeted cancer treatments. With a robust platform, the company addresses significant challenges in cancer care.Founded in 2018 and headquartered in Phoenix, US, OncoMyx, Inc. operates in the biotechnology sector, specializing in immuno-oncology solutions. The company is led by CEO Steven Potts. In November 2021, OncoMyx raised USD 50 mn in Series B funding from investors including B Capital Group and Lumira Ventures, among others, bringing the total amount raised to USD 50 mn.OncoMyx specializes in developing a novel immuno-oncology platform that focuses on delivering multiple cancer-killing payloads targeted at various cancers. Their solutions are designed to enhance the efficacy of cancer treatments, aiming to address the specific needs of oncologists and patients. The company targets various healthcare markets to improve cancer treatment outcomes effectively.OncoMyx generates revenue through its innovative therapeutic solutions and collaborations in the biotechnology field. The company's revenue model is structured around strategic partnerships and funding from investors that support the development of its product offerings, with plans to engage in further collaborations to expand its reach.Following its most recent funding round in November 2021, in which OncoMyx raised USD 50 mn in Series B funding, the company plans to utilize these resources to advance its immuno-oncology platform that delivers multiple cancer-killing payloads. OncoMyx aims to introduce new products designed for specific cancer treatments and expand its footprint in the North American and European markets by 2023, thereby enhancing its capabilities to meet diverse market demands.

## Funding rounds

- Series B, Nov 19, 2021, $50M — Boehringer Ingelheim Venture, City Hill Ventures, Korea Investment Partners, Xeraya Capital, Delos Capital Partners, Madison Partners, B Capital, Lyzz Capital, Lumira Ventures
- Series A, Jun 4, 2019, $8M — Jefferies, Boehringer Ingelheim Venture, City Hill Ventures, Korea Investment Partners, Xeraya Capital, Delos Capital Partners

## Investors

- Jefferies (https://capitalatlas.ai/funds/jefferies) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B
- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series A, Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series A, Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series A, Series B
- Madison Partners — Series B
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series B
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B